Use of Parapox B2L protein to treat cancer and modify immune responses
US6844000B2 · kind B2 · utility
0Cited by
11References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 6, 2002 |
| Grant date | Jan 18, 2005 |
| Priority date | — |
| Expiry date | Dec 6, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/24233
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A purified Parapoxvirus ovis envelope protein termed “B2L” can be used as a monotherapeutic agent. B2L protein also can be used in screening methods to identify potential therapeutic agents for modulating a subject's immune response to the B2L protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.